MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors is a research paper published in Journal for ImmunoTherapy of Cancer (2024). On theSindex it has a DataRank of 0.449. It has been cited 19 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.449
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →American Cancer Society
Grant: RSG-23-1155993-01-MM
Department of Defense
Grant: ME220215P1
Cancer Prevention and Research Institute of Texas
Grant: CPRIT scholar
Cancer Prevention and Research Institute of Texas
Grant: RP200520
Melanoma Research Alliance
Grant: 558998
National Institutes of Health
Grant: P50CA221703
National Institutes of Health
Grant: R01CA240700
National Institutes of Health
Grant: R35GM153387
NIGMS NIH HHS
Grant: R35 GM137927
National Institutes of Health
Grant: 5R01CA240700-04
Development and Mechanistic Studies of an Engineered Human Enzyme to Abrogate Immune Suppression due to Elevated Methylthioadenosine (MTA) by MTAP null/low Tumors
National Institutes of Health
Grant: 5R35GM153387-02
A Functional Analysis of Arginine Methylation
National Institutes of Health
Grant: 5P50CA221703-04
The University of Texas MD Anderson Cancer Center SPORE in Melanoma
FWCI
3.49
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords